KTTA

0.47870.48%
DH

Daniel H. Schneiderman

Chief Financial Officer

Mr. Daniel H. Schneiderman, also known as Dan, served as Chief Financial Officer at First Wave BioPharma, Inc. (formerly known as AzurRx BioPharma, Inc.) since January 02, 2020 until February 28, 2022. From December 17, 2018 to December 2019, he served as Chief Financial Officer of Biophytis SA and its U.S. subsidiary, Biophytis, Inc. Mr. Schneiderman served as a Vice President of Finance at MetaStat, Inc. since December 21, 2012 until 2018 and Secretary since February 27, 2012 until 2018 and served as its Controller since February 27, 2012 until August 2018. He served as Controller of MetaStat, Inc. from December 21, 2012 to October 22, 2015. He serves as Chief Financial Officer at Pasithea Therapeutics Corp. since October 11, 2022. He served as a senior vice president of Investment Banking for Burnham Hill Partners LLC, where he worked since 2008 till February 2012. From 2004 through 2008, Mr. Schneiderman served as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H. C. Wainwright & Co. in 2004 as an Analyst. Mr. Schneiderman serves as a Director of Unleashed, Inc., a not-for-profit organization located in New York, NY. He brings capital raising, strategic advisory and operational experience primarily with high-growth companies in the healthcare and life sciences industries. Mr. Schneiderman's early career included a number of investment banking positions where he focused on private and public small capitalization companies mainly in the healthcare and life sciences sectors. Mr. Schneiderman holds a Bachelor's Degree in Economics from Tulane University.

Positions